Biosimilar insulins: a E uropean perspective-Reference-Cited by-同舟云学术

Biosimilar insulins: a E uropean perspective

Published:2014-11-27 Issue:5 Volume:17 Page:445-451
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

DeVries J. H.¹,Gough S. C. L.²,Kiljanski J.³,Heinemann L.⁴

Affiliation:

1. Endocrinology Academic Medical Centre Amsterdam The Netherlands

2. Oxford Centre for Diabetes, Endocrinology and Metabolism NIHR Oxford Biomedical Research Centre Oxford UK

3. Eli Lilly and Company Warsaw Poland

4. Science & Co Düsseldorf Germany

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12410

Reference51 articles.

1. Biosimilar insulins

2. Global insulin market on the rise. PharmacoEconomics & Outcomes News2012;663:10.

3. Global insulin market expanded to $20.8 billion in 2012.2013. Available from URL:http://www.thepharmaletter.com/article/global‐insulin‐market‐expanded‐to‐20‐8‐billion‐in‐2012. Accessed 15 September 2014.

4. Sanofi.Annual results 2013.2014. Available from URL:http://en.sanofi.com/events/2013_Results/docs/2014‐02‐06_Results‐2013_presentation.pdf. Accessed 25 August 2014.

5. An analysis of the US biosimilars development pipeline and likely market evolution;Rader RA;BioProcess Int,2013

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Effectiveness of Multiple Switching Between Originators and Biosimilars: Literature Review and Status Report on Interchangeability;Therapeutic Innovation & Regulatory Science;2022-11-02

2. Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2021-01

3. Nanomedical Relevance of the Intermolecular Interaction Dynamics—Examples from Lysozymes and Insulins;ACS Omega;2019-02-27

4. Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins;Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease;2019

5. Développement des biosimilaires de l’insuline : exemple de l’insuline glargine LY2963016;La Presse Médicale;2018-10